Orrick advised Arcadia Biosciences Inc. on its initial public offering. Arcadia, a California-based biotech company founded in 2002, develops agricultural traits and products that enable plants to better withstand droughts, heat, salt, herbicides and varying availability of nitrogen. Targeting the $39.4 billion global seed market, Arcadia is developing higher yielding seeds for the most widely grown crops such as wheat, rice, soybean, corn and sugarcane, as well as other crops such as cotton, canola, turf and trees, with the goal of benefitting the environment and enhancing human health. The Company trades on The Nasdaq Global Market under the symbol “RKDA.”
The Orrick Capital Markets team representing Arcadia was led by corporate partners Karen Dempsey and Christopher Austin, supported by corporate associate Michael Hopp, and executive compensation partner Jason Flaherty. The team also included corporate associate Ahalya Sriskandarajah and law clerk Ryan Williams.
Orrick also recently advised Arcadia on a $20 million venture debt agreement that was led by banking & debt finance partner Zach Finley.